- Report
- October 2024
- 190 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- March 2025
- 192 Pages
Global
From €4727EUR$4,950USD£3,953GBP
- Report
- June 2024
- 200 Pages
Global
From €7593EUR$7,950USD£6,349GBP
- Report
- August 2022
- 115 Pages
Global
From €4298EUR$4,500USD£3,594GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- May 2023
- 84 Pages
Global
From €3500EUR$3,926USD£3,029GBP
Hypercalcemia is a condition in which the calcium levels in the blood are abnormally high. It is a common complication of hematological diseases, such as multiple myeloma and lymphoma. Treatment of hypercalcemia typically involves the use of drugs that reduce the absorption of calcium from the gut, increase its excretion from the body, or reduce its production in the bones. These drugs are known as hypercalcemia drugs and are used in combination with other treatments, such as hydration and diuretics.
Hypercalcemia drugs are typically administered orally or intravenously, depending on the severity of the condition. Commonly used drugs include bisphosphonates, calcitonin, and calcimimetics. Bisphosphonates are the most commonly used drugs for hypercalcemia, as they reduce the absorption of calcium from the gut and increase its excretion from the body. Calcitonin is a hormone that helps reduce the production of calcium in the bones, while calcimimetics are drugs that act on the parathyroid glands to reduce the production of parathyroid hormone, which is responsible for increasing calcium levels in the blood.
Some companies in the hypercalcemia drug market include Amgen, Novartis, Merck, and Eli Lilly. Show Less Read more